Ibnsina Pharma’s consolidated profits surge 68.4% YoY in H1 2024
Updated 8/14/2024 11:27:00 AM
Arab Finance: Ibnsina Pharma (ISPH) recorded a 68.4% year-on-year (YoY) increase in consolidated net profits after tax and non-controlling interest in the first half (H1) of 2024 to EGP 221.597 million, versus EGP 131.615 million, the firm disclosed.
Net sales came in at EGP 22.812 billion in the January-June period this year, up from EGP 14.697 billion in the same period last year.
The company’s standalone net profits after tax stood at EGP 228.25 million in H1 2024, rising from EGP 153.261 million in the corresponding half a year ago.
Meanwhile, standalone net sales increased to EGP 22.737 billion from EGP 14.647 billion.
Established in 2001, Ibnsina Pharma is the second-largest pharmaceutical distributor in Egypt, distributing products from over 350 global and local companies to more than 46,000 customers of pharmacies, hospitals, wholesalers, and healthcare institutions.
Related News
